It is an entirely adequate fundamental proposition though don’t you think Balance,
1. Ongoing internationally recognised quality research coming out of the University of Otago, for which Pacific Edge have access rights.
http://www.otago.ac.nz/ctcr/research...ago056099.html
2. Cost effective development, clinical trials and commercial readiness in NZ at a fraction of the work up cost required elsewhere.
3. Establishment of an in country commercialisation subsidiary company and a fully US management & sales team with prior sector contacts and experience.
Agree that ongoing monitoring of a five year goal is absolutely necessary as an investor, but we should not expect Pacific Edge to provide sales or revenue results more frequently than HY and FY reporting.
Other companies don’t do it and we must be equally as patient with Pacific Edge.
IMO we may or may not get an outlook slide at the AGM, maybe number of sales staff appointed, maybe at a stretch an estimation of tests to the end of the financial year.
It’s very unlikely we will get numerical sales guidance for exactly the same and fair reasons that were provided for shareholders at last year’s AGM.